122 related articles for article (PubMed ID: 17212003)
1. Controlled trial with interferon alfa 2-b in chronic hepatitis C patients.
El-Zayadi AR; Selim O; El-Haddad S; Ahdy A
J Egypt Public Health Assoc; 1994; 69(5-6):335-45. PubMed ID: 17212003
[TBL] [Abstract][Full Text] [Related]
2. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group.
Lin R; Roach E; Zimmerman M; Strasser S; Farrell GC
J Hepatol; 1995 Nov; 23(5):487-96. PubMed ID: 8583134
[TBL] [Abstract][Full Text] [Related]
3. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
4. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
[TBL] [Abstract][Full Text] [Related]
5. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
6. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
7. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
8. Fixed versus titrated interferon-alpha 2B in chronic hepatitis C. A randomized controlled multicenter trial. The Swiss Association for the Study of the Liver.
Reichen J; Bianchi L; Bühler H; Dolivo N; Gonvers JJ; Lavanchy D; Malé PJ; Renner EL; Solioz M; Schmid M; Zimmermann A
J Hepatol; 1996 Sep; 25(3):275-82. PubMed ID: 8895005
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
Blood; 1991 Oct; 78(7):1672-7. PubMed ID: 1912556
[TBL] [Abstract][Full Text] [Related]
10. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha.
Bresci G; Parisi G; Banti S; Capzia A
J Viral Hepat; 1995; 2(3):155-8. PubMed ID: 7493311
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in [corrected] patients with chronic hepatitis B lacking HBeAg in China [corrected].
You J; Zhuang L; Cheng HY; Yan SM; Qiao YW; Huang JH; Tang BZ; Ma YL; Wu GB; Qu JY; Wu RX
J Chin Med Assoc; 2005 Feb; 68(2):65-72. PubMed ID: 15759817
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
[TBL] [Abstract][Full Text] [Related]
13. Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.
Gaeta GB; Di Virgilio D; Russo G; Stornaiuolo G; Nicolella U; Colella F; Grimaldi M; Pasquale G; Giusti G
J Viral Hepat; 1997 May; 4(3):209-14. PubMed ID: 9181530
[TBL] [Abstract][Full Text] [Related]
14. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of recombinant interferon-alpha 2b in the treatment of Chinese patients with chronic hepatitis C.
Hwang SJ; Chan CY; Lu RH; Wu JC; Lee SD
J Interferon Cytokine Res; 1995 Jul; 15(7):611-6. PubMed ID: 7553231
[TBL] [Abstract][Full Text] [Related]
16. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.
Fernández JL; Rendo P; del Pino N; Viola L
J Viral Hepat; 1997 Mar; 4(2):113-9. PubMed ID: 9097267
[TBL] [Abstract][Full Text] [Related]
17. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of hepatitis B vaccination and interferon-alpha-2b combination therapy versus interferon-alpha-2b monotherapy in children with chronic hepatitis B.
Helvaci M; Kizilgunesler A; Kasirga E; Ozbal E; Kuzu M; Sozen G
J Gastroenterol Hepatol; 2004 Jul; 19(7):785-91. PubMed ID: 15209626
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection.
Puoti M; Rossi S; Forleo MA; Zaltron S; Spinetti A; Putzolu V; Rodella A; Carosi G
J Hepatol; 1998 Jul; 29(1):45-52. PubMed ID: 9696491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
